Cancer Letters

Cancer Letters

Volume 338, Issue 1, 10 September 2013, Pages 4-9
Cancer Letters

Mini-review
Acute myelogenous leukemia stem cells: From Bench to Bedside

https://doi.org/10.1016/j.canlet.2012.05.034Get rights and content

Abstract

Despite reaching remission with traditional chemotherapy, most adult patients with acute myeloid leukemia (AML) will relapse and die of their disease. Numerous studies have identified a rare subset of leukemia cells that evade traditional chemotherapy and are capable of self-renewal and initiating leukemia. These cells are thought to be responsible for relapse and are termed leukemia stem cells (LSCs). This article will review the current LSC translational research and focus on new approaches to detect LSC burden and its prognostic implications, as well as the identification and development of therapeutic agents active against LSCs.

Highlights

► Leukemia stem cells are a rare subset of cells capable of self-renewal and initiating leukemia. ► Studies show that high leukemia stem cell burden is associated with poor prognosis. ► Various pre-clinical and clinical trials targeting leukemia stem cells are in development.

Introduction

Despite much advancement in the treatment of acute myelogenous leukemia (AML) over the past three decades, the prognosis remains poor. New cytogenetic markers such as the Flt-3/ITD and NPM1 mutations now aid prognosis, but these discoveries have not translated to significant advancements in survival for the majority of patients with AML. Current chemotherapy regimens employing a backbone of cytarabine combined with an anthracycline have remained largely unchanged since 1973. This treatment regimen is capable of reducing the tumor burden (i.e. the total blast population) and produces a complete remission (CR) in almost 70% of patients. Despite this and the addition of allogeneic stem cell transplant in certain high-risk groups or in those with a matched sibling, most patients will ultimately relapse and approximately 60% of patients will succumb to their disease [1]. Pediatric patients below 15 years of age, while faring better, only have a survival rate approaching 60% [2].

Due to the high incidence of relapse in AML, it is clear that that there is a rare subset of malignant cells that are not effectively eliminated by current treatment regimens [3]. There is a growing opinion that these cells have stem cell-like properties and have been termed leukemia stem cells (LSCs). Independent of the specific cell that gives rise to LSCs, LSCs may share properties with normal hematopoietic stem or progenitor cells (HSCs/HPCs) that make them difficult to target with conventional cancer treatments [4]. Fundamental to their function is their ability to self-renew and give rise to more differentiated progeny. This allows them to maintain a small population of cells capable of recapitulating disease. Like HSCs, LSCs tend to be quiescent, remaining in G0. Furthermore, increasing evidence indicates that LSCs displace normal HSCs from their niche, appropriating its resources to maintain themselves [3], [5], [6]. Targeting LSCs has the promise to eradicate AML and will involve novel therapies that will exploit the differences between these cells and HSCs. This review will discuss strategies used to identify LSCs and developing therapies that selectively target them.

Section snippets

Identifying LSCs and their clinical implications

LSCs were initially characterized in human AML by Bonnet and Dick when they isolated subpopulations of cells from AML patient samples based on their immunophenotype, and xenotransplanted them into NOD/SCID mice. They discovered that the CD34+CD38- expressing subpopulation was exclusively capable of serially transplanting these immunodeficient mice [7]. This finding supported previous evidence of a functional leukemia initiating cell (LIC) defined by its ability to engraft immunocompromised mice

Targeting LSCs

Due to the relative resistance of LSCs to traditional cancer therapies such as chemotherapy, radiation and HSCT, new approaches are currently in development that specifically target the LSC population. LSCs have many attributes that distinguish them from the general blast population and make them more similar to stem cells. In order to eradicate LSCs, it is crucial to overcome the properties that can make them resistant to therapy such as their quiescence, ability to self-renew, and modify the

Disrupting the LSC microenvironment

Cells rely on interactions with other cells in order to function properly and LSCs are no exception. There is evidence from murine xenotransplant models that leukemic cells infiltrate the bone marrow niche, displace HSCs, and use the niche to create an environment hospitable for themselves [24]. Within this niche, LSCs are able to send and receive signals that influence their ability to self-renew, maintain their quiescence, activate pro-growth signals, and inactivate apoptosis pathways. These

Eliminating LSC self-renewal mechanisms

There are a variety of signaling pathways that allow HSCs to self-renew such as Notch, homeobox (HOX), hedgehog, and the Wnt/beta-catenin signaling pathways [40]. While the details of these signaling pathways in both HSCs and leukemia are still not completely known, there are indications that LSCs rely on these pathways for self-renewal. In a recent report by Wang et al. [41], the authors transformed either HSCs or granulocyte–macrophage progenitors (GMP) with either HOXA9 and MEIS1a oncogenes

Targeting LSC growth factors and regulators of apoptosis

Leukemia stem cells appear to be dependent on several survival pathways within the cell leading to aberrant growth and escape from apoptosis. It was previously demonstrated that nuclear factor kappa B activity is elevated in LSCs [43]. NF-κB is a transcription factor active in promoting growth and anti-apoptotic activity within the cell. NF-κB is normally inhibited by the Inhibitor of kappa B alpha (IkBa) family of proteins, which sequester the protein in the cytoplasm not allowing it to enter

Targeting cell surface antigens

Recently, many cell surface antigens have been described showing increased expression in LSCs as compared to HSCs, making these antigens potential therapeutic targets. These antigens include CD123, CD44, CLL-1, CD47, CD25 and CD32 [56]. Various ways of targeting cell surface antigens currently exist and are currently in clinical trials in many illnesses. These include monoclonal antibodies (Ab), immunotoxins, chimeric antigen receptor modified T-cells (CAR T-cells) and nanoparticles containing

Genomic approaches to targeting LSCs

The process of devising new drugs to target LSCs is hindered by the lack of a defined LSC phenotype. While surface markers can be used to identify populations enriched in LSC activity, the LSC potential of any one cell is unknown and the proportion of cells demonstrating LSC activity in functional assays is rather low. Thus, given the tremendous effort required to find a single compound, it is of interest to capture the molecular changes caused by known anti-LSC compounds to accelerate the

Conclusion

For decades, it has been known that there is a subpopulation of AML cells that are resistant to traditional cancer therapies and lead to relapse in the majority of patients with this disease. Over the past two decades, the ability to identify and sort different subpopulations of cells and engraft them into immunocompromised mice has allowed for the ability to define these cells as LSCs. These cells exhibit many qualities found in HSCs such as the ability to both self-renew and to give rise to

References (77)

  • L. Jin et al.

    Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells

    Cell Stem Cell

    (2009)
  • K. Takubo et al.

    Regulation of the HIF-1alpha level is essential for hematopoietic stem cells

    Cell Stem Cell

    (2010)
  • T. Simsek et al.

    The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche

    Cell Stem Cell

    (2010)
  • Y. Wang et al.

    Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies

    Cell Stem Cell

    (2011)
  • M.L. Guzman et al.

    Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

    Blood

    (2001)
  • W.E. Naugler et al.

    NF-kappaB and cancer-identifying targets and mechanisms

    Curr. Opin. Genet. Dev.

    (2008)
  • M.L. Guzman et al.

    The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells

    Blood

    (2005)
  • D.C. Hassane et al.

    Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways

    Blood

    (2010)
  • Z. Tothova et al.

    FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress

    Cell

    (2007)
  • J.C. Reed

    Bcl-2-family proteins and hematologic malignancies: history and future prospects

    Blood

    (2008)
  • G. Del Poeta et al.

    Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML)

    Blood

    (2003)
  • M. Konopleva et al.

    Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

    Cancer. Cell

    (2006)
  • A. van Rhenen et al.

    The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells

    Blood

    (2007)
  • D.C. Hassane et al.

    Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data

    Blood

    (2008)
  • J.H. Lee et al.

    Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid

    Biochem. Pharmacol.

    (2006)
  • G. Sethi et al.

    Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation

    Blood

    (2007)
  • S. Page et al.

    4-Hydroxynonenal prevents NF-kappaB activation and tumor necrosis factor expression by inhibiting IkappaB phosphorylation and subsequent proteolysis

    J. Biol. Chem.

    (1999)
  • M. Skrtic et al.

    Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia

    Cancer. Cell

    (2011)
  • Y. Eberhard et al.

    Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells

    Blood

    (2009)
  • G.J. Roboz

    Novel approaches to the treatment of acute myeloid leukemia

    Hematol. Am. Soc. Hematol. Educ. Program.

    (2011)
  • M.A. Smith et al.

    Outcomes for children and adolescents with cancer: challenges for the twenty-first century

    J. Clin. Oncol.

    (2010)
  • G.J. Roboz et al.

    Acute myeloid leukemia stem cells: seek and destroy

    Expert Rev. Hematol.

    (2009)
  • M.F. Clarke et al.

    Cancer stem cells–perspectives on current status and future directions: AACR workshop on cancer stem cells

    Cancer Res.

    (2006)
  • D. Bonnet et al.

    Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

    Nat. Med.

    (1997)
  • T. Lapidot et al.

    A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

    Nature

    (1994)
  • F. Ishikawa et al.

    Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region

    Nat. Biotechnol.

    (2007)
  • A. van Rhenen et al.

    High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival

    Clin. Cancer Res.: An Official J. Am. Associat. Cancer Res.

    (2005)
  • A.J. Gentles et al.

    Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia

    JAMA

    (2010)
  • Cited by (0)

    1

    Tel.: +1 212 639 2000.

    View full text